Bain, At­las, RTW back new biotech de­vel­op­ing obe­si­ty drugs with $400M

A new obe­si­ty biotech has en­tered the field — and it has $400 mil­lion from well-known life sci­ences in­vestors to test in­ves­ti­ga­tion­al GLP-1 and GIP can­di­dates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER